Clinical Guidelines for the Prescribing and Monitoring of Benzodiazepines and Related Medications

Introduction

Prescriptions for benzodiazepine medications (primarily for anxiety or insomnia) filled in the United States increased by 320% from 1996-2013. Over this same interval, overdose deaths associated with these medications increased over 500%.\(^1\) A portion of this increase in mortality is likely attributable to the higher dose per prescription observed, as well as the marked increase of opioid prescribing over this same period. The role of benzodiazepines in opioid overdose deaths nationwide increased from 18% of opioid overdose deaths in 2004 to 31% in 2011.\(^2\) In Philadelphia, the issue is even more remarkable, with a 2016 report finding that approximately 90% of all opioid overdose death also involved benzodiazepines.\(^3\)

While there are a number of legitimate uses for benzodiazepines and related medications, there is not yet a clear consensus as to how best to conceptualize their role in the pharmacotherapy of psychiatric disorders. This is particularly clear in Philadelphia, where the variation in benzodiazepine prescribing rates is remarkably high.

CBH seeks to promote practices to maximize access to evidence-based practices for individuals seeking treatment for anxiety and insomnia. This is best accomplished by limiting the initiation of benzodiazepines when more effective or safer options are readily available, given the high liability for these medications to complicate recovery from substance use disorders, or lead to “iatrogenic” benzodiazepine dependence. Tapering and discontinuing these medications once dependence has formed is very difficult. These guidelines should be understood to apply to benzodiazepine receptor agonists (e.g. zolpidem), in the case of sleep, as well as to barbiturates, and other less-commonly prescribed, controlled sedative-hypnotics, where even greater risks may exist.

---


Standard 1: Benzodiazepines should not be initiated as monotherapy for the treatment of anxiety disorders.

While there is evidence that benzodiazepines can be used safely and effectively for the treatment of anxiety, evidence-based guidelines recommend their reservation as second-line agents. Other pharmacologic treatments, primarily serotonin-norepinephrine reuptake inhibitors (SNRI) and selective serotonin reuptake inhibitors (SSRI) have the benefit of a much stronger base of clinical trial evidence to support as first-line use and have significant safety advantages. Nonpharmacologic treatments may also be considered as first-line treatments for multiple anxiety disorders; those focusing on cognitive-behavioral and exposure-based models have the strongest supporting evidence.

Exception:

Treatment should be individualized when possible to help support individuals’ recovery goals. When there is documented intolerance or poor response to first-line treatments for anxiety disorders (see figure below), then benzodiazepine monotherapy may be appropriate.

<table>
<thead>
<tr>
<th>First-line Pharmacologic Therapy for Anxiety Disorders</th>
</tr>
</thead>
<tbody>
<tr>
<td>Panic Disorder</td>
</tr>
<tr>
<td>Selective Serotonin Reuptake Inhibitors (SSRI)</td>
</tr>
<tr>
<td>Citalopram               X</td>
</tr>
<tr>
<td>Escitalopram             X</td>
</tr>
<tr>
<td>Fluoxetine               X</td>
</tr>
<tr>
<td>Fluvoxamine              X</td>
</tr>
<tr>
<td>Paroxetine               X</td>
</tr>
<tr>
<td>Sertraline               X</td>
</tr>
</tbody>
</table>

Serotonin-Norepinephrine Reuptake Inhibitors (SNRI)

| Venlafaxine               X                                           | X                             | X                        | | X |
| Duloxetine               X                                           |                              |                          |                                |                                |

Adapted from Bandelow et al., 2012. First-line here refers to medications supported fully by clinical trial evidence and that gave a good risk/benefit ratio. Discussion of methods for grading of evidence and risk/benefit discussed more fully in Bandelow et al., 2008.


5 Borwin Bandelow , Leo Sher, Robertas Bunevicius , Eric Hollander, Siegfried Kasper, Joseph Zohar, Hans-Jürgen Möller 6, WFSBP Task Force On Mental Disorders In Primary Care and WFSBP Task Force on Anxiety Disorders , OCD and PTSD
Standard 2: Benzodiazepines should not be used for the treatment of insomnia without appropriate evaluation, and should not be used chronically.

Prior to the initiation of benzodiazepines or benzodiazepine receptor agonist medications, a thorough evaluation for underlying causes of secondary insomnia should be performed and documented. This evaluation should screen for sleep-related breathing disorders (e.g. obstructive sleep apnea), sleep-related movement disorders (e.g. restless legs syndrome), adverse medication or caffeine effects, behavioral causes (e.g. poor sleep hygiene), and psychiatric syndromes known to cause insomnia. Individuals should also be screened for other contraindications discussed in these guidelines. When benzodiazepines are used for the treatment of insomnia, an initial treatment period of 2-4 weeks is recommended, as many individuals will remain asymptomatic after tapering at this point.

Exception:

Some individuals may experience chronic insomnia that recurs with attempts to taper, beyond expectable and short-term rebound insomnia. In such cases, longer-term treatment may be acceptable, provided there is appropriately documented rationale. Referral for sleep medicine evaluation or behavioral sleep therapy should also be considered.

Standard 3: Benzodiazepines should not be prescribed to individuals with substance use disorders.

Benzodiazepines have a significant liability for abuse; in order to avoid complicating the recovery of individuals with substance use disorders, a thorough screening for past and current substance use disorder must be documented prior to the prescribing of benzodiazepines. For the purposes of such an evaluation, individual self-report cannot be the only source of information: a treatment history from CBH member services, collateral information from other providers, or urine drug screening are acceptable methods of objective assessment. Individuals with current or past substance use disorders should rarely, if ever, be prescribed benzodiazepines.

Exception:

There may be cases where therapy with benzodiazepines is medically necessary despite substance use. Thorough documentation of medical decision making and the steps taken to protect the individual from harm is required. A plan to assess for abuse or diversion of medications in an ongoing fashion must also

---


8 “Drug diversion” is best defined as the diversion of licit drugs for illicit purposes. It involves the diversion of drugs from legal and medically necessary uses towards uses that are illegal and typically not medically authorized or necessary.
be documented. Urine drug screening is typically the simplest method. Evidence of persistent or repeated substance use, medication diversion, or other aberrant medication-related behavior should be addressed via behavioral contract specifying tapering, referral to an alternate level of care, or administrative discharge. Such an exception will not apply when the individual is actively using illicit opioids.

**Standard 4: Benzodiazepines should not be prescribed to individuals enrolled in medication-assisted therapy (MAT) for opioid use disorders, or who are prescribed chronic opioid medications for pain.**

Given the danger (discussed above) represented by the combination of benzodiazepines and opioids, such a combination is contraindicated.\(^9\)

*Exceptions:*

Initiation of benzodiazepines for individuals receiving MAT or opioids must be accompanied by documentation that such prescribing adheres to all other standards of this guideline, documented rationale establishing medical necessity, and ongoing collaboration between both prescribing providers.

In some cases, individuals will be encountered who have been maintained on chronic opioids and chronic benzodiazepines. In such cases, a rapid discontinuation of either medication is neither practical nor safe. Continued treatment must be accompanied by documented collaboration between the providers of each medication, and a documented plan to taper one or both medications (or documentation of why this is impossible).

**Standard 5: Benzodiazepines and other controlled substances will be prescribed in accordance with state requirements related to the prescription drug monitoring program (PDMP).**

In 2014, the Pennsylvania state legislature passed Act 191, expanding the state’s prescription drug monitoring program to include monitoring of all schedule II-V controlled substances. Beginning in August 2016, all prescribers now have legal responsibilities related to the use of the PDMP:

Per Act 191 of 2014, prescribers shall query the system for each individual the first time they prescribe the individual a controlled substance:

- For purposes of establishing a baseline and a thorough medical record; or

---

• If a prescriber believes or has reason to believe, using sound clinical judgment, that an individual may be abusing or diverting drugs.

Documentation requirements are straightforward: a prescriber shall indicate the information obtained from the system in the individual's medical record if:

• The individual is a new individual; or
• The prescriber determines a drug should not be prescribed or furnished to an individual based on the information from the system.

When query of the PDMP reveals potential concerns, and controlled substances are still to be prescribed, documentation that standards 1-4 are being adhered to will be required.

It is also important to note that controlled substances prescribed for medication-assisted treatment (MAT) of opioid use disorders (e.g. methadone) will not appear in PDMP reports, and this system cannot be relied upon for information about such medications.

Registration for the PDMP (required for all PA prescribers) and further information can be found at: http://www.health.pa.gov/Your-Department-of-Health/Offices%20and%20Bureaus/PaPrescriptionDrugMonitoringProgram/Pages/PDMP-Portal.aspx#.V9LAp1srKJA

**CBH Implementation Review**

Providers must develop a policy to ensure the prescribing of benzodiazepines and other sedative-hypnotic medications (e.g. barbiturates, benzodiazepine receptor agonists, etc.) adheres to these standards. The policy and related practices must also align with relevant CBH, state, and federal regulations and standards, including CBH prescribing bulletins (e.g. Bulletin 07-07 Screening for and Treatment of the Components of Metabolic Syndrome\(^\text{10}\)), the Network Inclusion Criteria Standards of Excellence,\(^\text{11}\) and the DBHIDS Practice Guidelines for Resiliency and Recovery-oriented Treatment.\(^\text{12}\)

The required policies will be reviewed by CBH and NIAC during initial and re-credentialing for adequate incorporation of the prescribing standards discussed above and any alignment with relevant federal, state, and CBH guiding documents. Clinical documentation related to this policy may also be reviewed. CBH will monitor prescribing of benzodiazepines by providers via claims data across levels of care to assess adherence and for opportunities for quality improvement interventions. CBH will also monitor

---

\(^{10}\) Department of Behavioral Health and Intellectual Disability Services (DBHIDS), *Bulletin 07-07 Screening for and Treatment of the Components of Metabolic Syndrome*

\(^{11}\) Department of Behavioral Health and Intellectual Disability Services (DBHIDS), *Philadelphia Behavioral Health Practice Guidelines*, 2013 (or most recent version)

\(^{12}\) Department of Behavioral Health and Intellectual Disability Services (DBHIDS), *Network Inclusion Criteria*, 2013, (or most recent version)
progress notes and any other related chart documentation to ensure these standards are being followed.